ArticleNEJM evidence2023
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.
Open access · greenAbstract read
In one paragraph
Article in NEJM evidence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-Analysis.Journal of acquired immune deficiency syndromes (1999) · 2024Pooled it
- Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.BMC cancer · 2026Trial
- Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial.Nature communications · 2026Trial
- Evaluating B/F/TAF at the first HIV-specialist appointment in antiretroviral naive persons living with HIV: the bifast study.BMC infectious diseases · 2026Trial
- Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Trial
- Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.Kidney international · 2024Trial
- The effect of oral probiotics on CD4 count in patients with HIV infection undergoing treatment with ART who have had an immunological failure.Immunity, inflammation and disease · 2023Trial
- Observational
- A combined eGFR-CD4 index and mortality risk among people with HIV: a retrospective cohort study in Taizhou city, Zhejiang province, China.AIDS research and therapy · 2026Article
- Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.The lancet. HIV · 2026Article
- Data-driven Modeling of Long-term CD4 Cell Recovery Trajectories Under Modern Antiretroviral Therapy in People Living With HIV.Open forum infectious diseases · 2026Article
- European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.Molecular oncology · 2026Review
- Comparison of clinical characteristics in acute and early HIV-1 infection across different subtypes: a hospital-based cohort study.Frontiers in microbiology · 2026Article
- Epidemiological yield and cost-effectiveness of non-targeted community HIV screening in a low-prevalence district: a prospective quasi-experimental study.Frontiers in public health · 2026Article
- Assessing the Benefits of Rapid Start Antiretroviral Therapy for Newly Diagnosed People with HIV in the United States.Advances in therapy · 2025Article
- A Closer Look at the Perceived Factors Contributing To Late HIV Diagnoses: A Qualitative Study among People with HIV.AIDS and behavior · 2025Article
- Angiogenic CD8 T cells from PWH induce Granzymes-dependent PAR1 activation promoting endothelial inflammation.bioRxiv : the preprint server for biology · 2025Article
- Combined screening of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in an emergency department: The URDEPTRIO cross-sectional study.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025Article
- Early versus deferred antiretroviral therapy initiation and long-term cardiovascular disease outcomes in people with HIV: The START study.Open forum infectious diseases · 2025Article
- Trend and Associated Factors for Late and Advanced HIV Diagnoses in 2011-2022 in Melbourne, Australia.Journal of medical virology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
72 authors at 1 institution in 1 country.
Jens D LundgrenCHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen.
Abdel G BabikerMedical Research Council Clinical Trials Unit, University College London, London.
Shweta SharmaDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis.
Birgit GrundSchool of Statistics, University of Minnesota, Minneapolis.
Andrew N PhillipsInstitute for Global Health, University College London, London.
Gail MatthewsKirby Institute, Sydney.
Virginia L KanVA Medical Center, Washington, D.C.
Bitten AagaardCHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen.
Inka AboHelsinki University Central Hospital, Helsinki.
Beverly AlstonDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Alejandro Arenas-PintoMedical Research Council Clinical Trials Unit, University College London, London.
Anchalee AvihingsanonThai Red Cross AIDS Research Centre, Bangkok, Thailand.
Sharlaa Badal-FaesenClinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.
Carlos BritesHospital Universitario Professor Edgard Santos, School of Medicine, Federal University of Bahia, Salvador, Brazil.
Cate CareyKirby Institute, Sydney.
Jorge CassebLaboratory of Medical Investigation - LIM56, Faculty of Medicine, Department of Dermatology, University of São Paulo, São Paulo.
Amanda ClarkeRoyal Sussex County Hospital, Brighton, United Kingdom.
Simon CollinsHIV i-Base, London.
Giulio Maria CorbelliEuropean AIDS Treatment Group, Brussels.
Sounkalo DaoMali-National Institute of Allergy and Infectious Diseases HIV Research Initiative, Bamako, Mali.
Eileen T DenningDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis.
Sean EmeryUNSW Medicine, Sydney.
Nnakelu EriobuInstitute of Human Virology Nigeria, Abuja, Nigeria.
Eric FlorenceInstitute of Tropical Medicine, Antwerp, Belgium.
Hansjakob FurrerDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Gerd FätkenheuerKlinik I für Innere Medizin der Universität zu Köln, Cologne, Germany.
Jan GerstoftRigshospitalet, Infektionsmedicinsk ambulatorium 8622, Copenhagen.
Magnus GisslénSahlgrenska University Hospital, Gothenburg, Sweden.
Katharine GoodallMedical Research Council Clinical Trials Unit, University College London, London.
Keith HenryHennepin Health Research Institute, Minneapolis.
Andrzej HorbanWojewódzki Szpital Zakaźny, Warsaw, Poland.
Jennifer HoyDepartment of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.
Fleur HudsonMedical Research Council Clinical Trials Unit, University College London, London.
Raja Iskandar Shah Raja AzwaUniversity Malaya Medical Centre, Kuala Lumpur, Malaysia.
Eynat KedemRambam Medical Center, Haifa, Israel.
Anthony KelleherKirby Institute, Sydney.
Cissy KityoJoint Clinical Research Centre, Kampala, Uganda.
Karin KlingmanDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Alberto La RosaAsociación Civil IMPACTA Salud y Educación, Lima, Peru.
Nicolas LeturqueINSERM SC10-US19, Villejuif, Paris.
Alan R LifsonUniversity of Minnesota, Minneapolis.
Marcelo LossoHospital General de Agudos J.M. Ramos Mejia, Buenos Aires.
Joseph LutaakomeMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Juan Sierra MaderoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City.
Patrick MallonCentre for Experimental Pathogen Host Research, University College Dublin, Dublin.
Kamal MansinhoHospital de Egas Moniz, Lisbon, Portugal.
Kamal Marhoum El FilaliUniversity Hospital Centre Ibn Rochd, Casablanca, Morocco.
Jean-Michel MolinaHôpital Saint-Louis, Paris.
Daniel D MurrayCHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen.
Kumarasamy NagalingeswaranVoluntary Health Services, Infectious Diseases Medical Centre, Chennai Antiviral Research and Treatment, Clinical Research Site, Chennai, India.
Silvia NozzaOspedale San Raffaele S.r.l., Milan.
Vidar OrmaasenOslo University Hospital, Ullevål, Oslo.
Roger ParedesHospital Universitari Germans Trias i Pujol, Barcelona.
Luiz Carlos PeireiraInstituto de Infectologia Emílio Ribas, São Paulo.
Sandy PillayDurban International Clinical Research Site, Durban, South Africa.
Mark N PolizzottoClinical Hub for Interventional Research, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia.
Dorthe RabenCHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen.
Armin RiegerUniversity Vienna General Hospital, Vienna.
Adriana SanchezVA Medical Center, Washington, D.C.
Mauro SchechterProjeto Praça Onze, Rio de Janeiro.
Dalibor SedlacekUniversity Hospital Plzen, Plzen, Czech Republic.
Therese StaubCentre Hospitalier de Luxembourg, Luxembourg.
Giota TouloumiMedical School, National and Kapodistrian University of Athens, Athens.
Melissa TurnerVA Medical Center, Washington, D.C.
Jose Valdez MadrugaCentro de Referência e Treinamento em DST/AIDS, São Paulo.
Michael VjechaVA Medical Center, Washington, D.C.
Marcelo WolffHospital Clínico San Borja Arriarán, Fundación Arriarán, Santiago, Chile.
Robin WoodDesmond Tutu Health Foundation, Cape Town, South Africa.
Kai ZilmerWest Tallinn Central Hospital Infectious Diseases, Tallinn, Estonia.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, Bethesda, MD.
James D NeatonDivision of Biostatistics, School of Public Health, University of Minnesota, Minneapolis.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group
Centre of Excellence for Health, Immunity and Infections · DK
Funding
Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0MNIAID NIH HHS U01 AI136780
Abstract
backgroundFor people with HIV and CD4
methodsThe Strategic Timing of AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults with CD4
resultsThrough December 31, 2015, approximately 7 months after the cutoff date from the previous report, the median CD4
conclusionsAmong adults with CD4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.